Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||clear cell renal cell carcinoma||not applicable||Ipilimumab + Nivolumab||Phase II||Actionable||In a Phase II trial (HCRN GU16-260), salvage therapy with combination of Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a partial response in 11% (3/27) and stable disease in 30% (8/27) of patients with advanced clear cell renal cell carcinoma whose disease progressed after Opdivo (nivolumab) monotherapy (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 5006-5006; NCT03117309).||detail...|
|PubMed Id||Reference Title||Details|
|Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).||Full reference...|